Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malluche, H. H.
Right arrow Articles by Monier-Faugere, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malluche, H. H.
Right arrow Articles by Monier-Faugere, M. C.

Journal of the American Society of Nephrology, Vol 4, 1631-1642, Copyright © 1994 by American Society of Nephrology

REVIEWS

The role of bone biopsy in the management of patients with renal osteodystrophy

HH Malluche and MC Monier-Faugere

Renal osteodystrophy is not a uniform disease. Therefore, knowledge of the underlying bone abnormalities is essential in deciding specific therapeutic regimens. To date, however, there is no unequivocal noninvasive means with which to define bone abnormalities accurately. The best tool remains mineralized bone histology requiring bone biopsies. Despite recent technical improvements, this technique is underused because of perceived constraints. This article outlines the procedures necessary for increasing the value of bone biopsies, such as tetracycline labeling, and various biopsy techniques and their potential complications. Bone biopsies provide important information on precisely the type of renal bone disease affecting patients: (1) predominant hyperparathyroid bone disease; (2) low-turnover uremic osteodystrophy, encompassing osteomalacic and adynamic renal bone disease; and (3) mixed uremic osteodystrophy, consisting of mild to moderate hyperparathyroid bone disease and defective mineralization. Also, the degree of the severity of the lesions may be assessed. Finally, the presence and quantity of aluminum deposition in bone can be demonstrated. The determination of aluminum overload is needed before the initiation of any therapeutic regimens because it is well known that potentially serious complications can occur with current treatments such as vitamin D therapies, desferoxamine administration, or parathyroidectomy.


This article has been cited by other articles:


Home page
 NDT PlusHome page
V. M. Brandenburg and J. Floege
Adynamic bone disease--bone and beyond
NDT Plus, June 1, 2008; 1(3): 135 - 147.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Botolin, M.-C. Faugere, H. Malluche, M. Orth, R. Meyer, and L. R. McCabe
Increased Bone Adiposity and Peroxisomal Proliferator-Activated Receptor-{gamma}2 Expression in Type I Diabetic Mice
Endocrinology, August 1, 2005; 146(8): 3622 - 3631.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M.-C. MONIER-FAUGERE, H. MAWAD, Q. QI, R. M. FRIEDLER, and H. H. MALLUCHE
High Prevalence of Low Bone Turnover and Occurrence of Osteomalacia after Kidney Transplantation
J. Am. Soc. Nephrol., June 1, 2000; 11(6): 1093 - 1099.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
R. A. Yokel, K. A. Meurer, C. B. Hong, K. M. Dickey, T. L. Skinner, and A. M. Fredenburg
Short-Term Oral 3-Hydroxypyridin-4-one Dosing Increases Aluminum Excretion and Partially Reverses Aluminum-Induced Toxicity in the Rabbit Independent of Chelator Lipophilicity
Drug Metab. Dispos., February 1, 1997; 25(2): 182 - 190.
[Abstract] [Full Text]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673